Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects.
Boehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment for patients with schizophrenia.
AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks set to repeat that success in renal disease after reporting stella
A fellowship programme is looking for digital pioneers to design and lead service transformation projects in England's NHS as the COVID-19 pandemic continues.
The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi